SurgeX

Surge Therapeutics is a clinical-stage biotechnology company developing a novel intraoperative immunotherapy platform designed to prevent cancer recurrence after surgery. The company's proprietary SurgeX platform utilizes a biodegradable hydrogel to deliver high concentrations of immunotherapy directly into the surgical site immediately following tumor resection. This approach aims to eliminate residual cancer cells and activate a systemic immune response while minimizing the toxicity associated with traditional systemic treatments. Surge's lead candidate, SURG-001, is currently being evaluated in clinical trials for patients with bladder cancer and other solid tumors. By targeting the critical window of perioperative care, Surge Therapeutics seeks to improve long-term survival outcomes for cancer patients undergoing surgical intervention.